Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 4,084,085	$ 1,477,143
Grants receivable	757,562	84,344
Prepaid expenses	419,751	334,629
Other current assets	47,586	14,675
Total current assets	5,308,984	1,910,791
Property and equipment, net	135,486	57,053
Goodwill	6,826,003	6,826,003
Other long term assets	126,654	11,017
Total assets	12,397,127	8,804,864
Current liabilities:
Accounts payable	3,002,497	1,313,247
Accrued compensation	562,755	230,381
Accrued clinical operations and site costs	391,041	494,110
Accrued lease contingency fee	590,504	590,504
Other accrued expenses	411,566	245,421
Warrant liability	0	92,463
Total current liabilities	4,958,363	$ 2,966,126
Commitments and contingencies:
Redeemable convertible preferred stock:
MabVax Therapeutics Holdings Series B redeemable convertible preferred stock, 1,250,000 shares authorized, none and 1,250,000 issued and outstanding as of December 31, 2015 and 2014, respectively, with a liquidation preference of $2,627,123 as of December 31, 2014	0	$ 1,838,025
Total redeemable convertible preferred stock	0	1,838,025
Stockholders' equity (deficit):
Common stock, $0.01 par value; 150,000,000 shares authorized as of December 31, 2015, 28,391,072 and 2,802,867 shares issued and outstanding as of December 31, 2015 and 2014, respectively	283,911	28,029
Additional paid-in capital	67,754,383	24,492,450
Accumulated deficit	(60,601,778)	(24,550,308)
Total stockholders' equity	7,438,764	4,000,713
Total liabilities, redeemable convertible preferred stock and stockholders' equity	12,397,127	8,804,864
Series A-1 Preferred Stock [Member]
Stockholders' equity (deficit):
Convertible preferred stock	0	4,029,576
Series C Preferred Stock [Member]
Stockholders' equity (deficit):
Convertible preferred stock	0	966
Series D Preferred Stock [Member]
Stockholders' equity (deficit):
Convertible preferred stock	1,915	0
Series E Preferred Stock [Member]
Stockholders' equity (deficit):
Convertible preferred stock	$ 333	$ 0